What is HC Wainwright’s Estimate for RVPH FY2025 Earnings?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Investment analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for shares of Reviva Pharmaceuticals in a research note issued on Tuesday, December 23rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.32) per share for the year, up from their prior forecast of ($0.42). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q4 2025 earnings at ($0.06) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.25) EPS.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.05.

Several other research analysts also recently weighed in on RVPH. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Wednesday, October 8th. Chardan Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Benchmark lowered their target price on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a report on Monday, September 15th. D. Boral Capital reaffirmed a “buy” rating and issued a $2.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday. Finally, Wall Street Zen upgraded Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, October 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $3.86.

Reviva Pharmaceuticals Trading Down 11.6%

Shares of NASDAQ RVPH opened at $0.28 on Thursday. The stock has a fifty day simple moving average of $0.56 and a two-hundred day simple moving average of $0.52. Reviva Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $2.17. The firm has a market cap of $32.68 million, a price-to-earnings ratio of -0.62 and a beta of -0.02.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. 683 Capital Management LLC purchased a new position in shares of Reviva Pharmaceuticals during the 2nd quarter worth approximately $381,000. Persistent Asset Partners Ltd boosted its position in shares of Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after purchasing an additional 480,864 shares in the last quarter. Armistice Capital LLC bought a new stake in shares of Reviva Pharmaceuticals during the second quarter valued at approximately $1,026,000. Millennium Management LLC grew its stake in Reviva Pharmaceuticals by 15.0% in the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after purchasing an additional 223,178 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares in the last quarter. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals News Summary

Here are the key news stories impacting Reviva Pharmaceuticals this week:

• Positive Sentiment: Analyst bullishness — HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target, implying large upside versus the current price; this bullish call likely fuels speculative interest. Read More.
• Positive Sentiment: Additional buy reiteration — D. Boral Capital maintained a “buy” rating with a $2.00 target, another institutional endorsement that can support upside momentum. Read More.
• Positive Sentiment: Heavy call option buying — traders purchased large volumes of call options (roughly 25,745 calls, ~295% above typical volume), which indicates speculative bullish positioning that can amplify intraday price moves. Read More.
• Neutral Sentiment: Short-interest data flagged as zero/incomplete — reported short interest shows 0 shares (data appears unreliable/NaN change), so it provides no clear signal on short-seller positioning. No meaningful short-squeeze implication from this report.
• Negative Sentiment: Regulatory setback — the FDA recommended a second Phase 3 trial for brilaroxazine in schizophrenia after a pre-NDA meeting, meaning more time, data and cost before potential approval; this is the primary driver of the stock decline. Read More.
• Negative Sentiment: Funding and dilution risk — analysts (Roth) warn Reviva may need an additional $60M–$75M to complete the schizophrenia study, raising dilution and financing concerns that weigh on valuation. Read More.
• Negative Sentiment: Price-target cuts and market reaction — Roth lowered its price target to $1.50 (from $3), and coverage/ headlines note a sharp intraday plunge after the FDA news, reinforcing negative sentiment and selling pressure. Read More. Read More.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.